On August 20 , 2022 , the 2022 Dezhou Drug Inspection and Testing Skills Competition was held as scheduled. A young team composed of Gao Wenjing, Liu Zhongchao, Zhang Shuhua, Li Xiaomin and Jia Binbin from Lonno Pharmaceuticals participated in the competition
On April 15, 2022, the State Drug Administration approved the production and marketing of lacosamide oral solution (Guoyao Zhunzi H20223222), and Shandong Langnuo Pharmaceutical Co., Ltd. became the first company in China to successfully imitate it.
On the morning of May 21, 2021, on the special day when Shandong Longnuo Pharmaceutical Co., Ltd. ushered in its 9th birthday, the group leaders and all employees of Longnuo Pharmaceutical participated in the flag-raising ceremony to celebrate the ninth anniversary of the establishment of Longnuo Pharmaceutical. Best wishes for the ninth birthday of the pharmaceutical company!
From October 16 to October 20, 2020, appointed by the Food and Drug Inspection Center of the State Drug Administration and the Inspection Center of the Shandong Provincial Drug Administration, a six-member inspection team inspected the R&D site of Bainuo Pharmaceuticals and the production site of Lonno Pharmaceuticals A 5-day on-site inspection of drug registration and GMP compliance inspection of desloratadine API was carried out.
From October 16 to October 20, 2020, appointed by the Food and Drug Inspection Center of the State Drug Administration and the Inspection Center of the Shandong Provincial Drug Administration, a six-member inspection team inspected the R&D site of Bainuo Pharmaceuticals and the production site of Lonno Pharmaceuticals A 5-day on-site inspection of drug registration and GMP compliance inspection of desloratadine API was carried out.
From June 28 to June 30, 2020, the inspection team of Shandong Drug Administration conducted a 3-day on-site inspection of the GMP compliance of lamivudine tablets to our company.